Abstract
AbstractCombination therapy was an effective strategy to overcome the limitations of many monotherapies. Here, hollow mesoporous titanium dioxide nanomaterials (TiO2) were synthesized by silica‐protected calcination‐alkali etching for loading adriamycin (DOX) with polydopamine (PDA) coating and then hyaluronic acid (HA) modification. The nanomaterials allowed for drug‐targeted delivery and the combination of photothermal therapy and chemotherapy. The hollow mesoporous titanium dioxide provided a high drug loading capacity, and the photothermal agent PDA layer exhibited good photothermal conversion capabilities. Moreover, the ability to target through hyaluronic acid‐mediated target allowed the nanomaterials targeted to human breast cancer cells (MCF‐7). Cytotoxicity and apoptosis tests showed that the prepared DOX@TiO2@PDA@HA showed potential as a drug delivery system for combined chemotherapy and photothermal therapy to improve anti‐tumor efficiency.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
